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. Furthermore, the expression levels of YKL-40 in human breast cancer were found to positively correlate with blood vessel formation. These findings have markedly enhanced our understanding of the molecular mechanisms of YKL-40 in the regulation of tumor angiogenesis and progression.
Tumor angiogenesis is an integral component of solid tumor growth and metastasis. Elevated levels of angiogenic factors such as VEGF and bFGF in cancer tissues directly correlate with tumor angiogenesis and tumor progression (20) (21) (22) . To support these angiogenic properties, multiple complementary studies using neutralizing antibodies, including a humanized anti-VEGF antibody (bevacizumab, Avastin), showed profound impacts in restriction of tumor growth (23) (24) (25) . Unfortunately, to date, functional inhibition of YKL-40 in human diseases and animal models has not been explored. Our current study sought to establish a monoclonal anti-YKL-40 antibody as a neutralizing agent for the purpose of blocking tumor angiogenesis and metastasis. Our findings highlight the potential therapeutic benefits of anti-YKL-40 treatment in patients with a wide spectrum of cancers that over-express YKL-40. Anti-YKL-40 antibodies: rAY was generated from the immunization of rabbits with a short peptide of YKL-40 encoding C-terminus of YKL-40. Crude serum was then purified through an Econo-Pac serum IgG purification kit (BioRad, Hercules, CA). mAY was created from a hybirdoma technology in which mice were initially immunized with YKL-40 recombinant protein as an antigen. Five positive hybridoma clones were screened twice with ELISA assay using recombinant YKL-40-precoated 96-well plates.
Two clones with highest binding activity were further evaluated by immunoblotting and functional analysis. Finally, one clone with strong binding activity and neutralizing activity was selected and grown for the study. Its culture medium was consequently GGTGCAGTACCTGAAGGAT 3' (siRNA 2) were selected and engineered into templates (64 oligo nucleotides) containing these oligos were subcloned into a retroviral pSUPER-puro-vector. 293T retroviral packaging cells were transfected with pSUPER siRNA constructs in the presence of pCL 10A1 vector using Fugene 6 (Roche). Fortyeight hours after transfection, the supernatant was harvested and filtered through 0.45-m pore size filter and then the viral medium was used to infect MG63 cells. Selection with 1 g/ml of puromycin was started 48 hr after infection and the purimycin-resistant cell populations were used for subsequent studies. Cell viability assay: U87 cells were treated with 10 Gy -irradiation in the of presence 10 g/ml mIgG or mAY. At 48-hr culture, the cells were imaged for cell detachment. 96 hr following culture, the cells were subjected to live and dead analysis using a Live/Dead kit in which ethidium homodimer is used to detect dead cells and calcein is used to test live cells (Invitrogen Inc).
Immunoprecipitation and Western Blot Analysis:
The samples were prepared as described before (27). The lysates were then incubated with an anti-pY20 antibody at 4 0 C overnight followed by incubation with protein A sepharose beads at 4 0 C for 4 hr.
The immunocomplex was extensively washed and the samples were run on SDS-PAGE. SCID/Beige mice were subcutaneously injected with U87 cells (7.5 x 10P P P Tumor growth from these injected cells was monitored weekly for 5 weeks before the animals were humanely sacrificed. Tumors were measured and tumor volume was calculated as follows: volume = length x widthP P P 2 P P P x 0.52.
Immunohistochemistry:
Frozen tumor tissues from animals were cut to 6 m thickness and processed for the staining of CD31. In brief, the samples were incubated with 3% H 2 O 2 for 30 min to block endogenous peroxidase activity followed by incubation with blocking buffer containing 10% goat serum for 1 hr. Then, a rat anti-CD31 monoclonal antibody (1: 500, BD Biosciences) was incubated at room temperature for 2 hr and a goat anti-rat secondary antibody (1: 100) conjugated with HRP was added. Finally, DAB substrate (Dako Inc) was introduced for several minutes and after washing, methyl green was used for counterstaining. 
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with mAY for 48 hr, they displayed a phenotype indicative of failure to survive, as more than 80% of these cells were detached from culture plates compared with the counterparts that showed 30% of detached cells in the absence of mAY ( Figure 5B ). To assess whether these cells undergo apoptosis, culture was extended to 96 hr and mAY treatment led to cell death around 1.5-fold greater than control or mIgG treated cells ( Figure 5B ).
To further determine whether the PI3K-AKT signaling cascade mediates the YKL-40-induced cell survival activity, we collected cell lysates and measured the expression of these proteins using immunoblotting. Intriguingly, mAY treatment led to decreases in activated AKT and non-activated AKT by 65-82%, but did not affect PI3K expression ( Figure 5C ) or kinase activity (data not shown), suggesting that YKL-40-mediated cell survival is AKT-dependent, but PI3K-independent. We next questioned whether the upregulation of YKL-40 by -irradiation is capable of prompting endothelial cell angiogenesis through a paracrine fashion, which may support tumor cell survival in vivo.
To address this, we collected the conditioned medium of U87 cells treated withirradiation and transferred to HMVECs for the tube formation assay. The medium from -irradiation-treated cells increased tubules two-fold more than did the control medium ( Figure 5D ). However, mAY completely abrogated the angiogenic effects of YKL-40 in HMVECs, strongly suggesting that mAY be used as an efficacious agent for the treatment of radioresistant cancers. 
were treated with either mAY or mIgG as a control (5 mg/kg body weight, subcutaneously) twice a week for two weeks. As demonstrated in Figure 6A has been established previously (34) (35) (36) . Consistent with our results, MAPK and AKT were reported to mediate YKL-40-induced mitogenic signaling in connective tissue cells (4) . In addition, we interestingly found that mAY nullified endothelial cell angiogenesis induced by U87 conditioned medium treated with -irradiation. Therefore, our studies offered mechanistic insight into radioresistance of cancers that express increased levels of YKL-40 and demonstrate poor prognosis (18, 37) . Furthermore, our findings shed light on the pronounced impacts of YKL-40 neutralizing antibody on cancer progression in conjunction with radiation therapy.
In current cancer therapy, particular attention has been focused on a number of anti-angiogenic drugs approved by FDA such as anti-VEGF antibody bevacizumab and VEGF receptor tyrosine kinase inhibitors (sorafenib and sunitinib). However, the benefits of these anti-angiogenic agents appear to be transitory in the treatment of several types of advanced cancers, as drug resistance, tumor regrowth, and extensive vascular recovery rapidly develop once the therapy is terminated (38) (39) (40) 
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therapies is believed to be associated with the angiogenic switch by which tumors undergo robust revascularization and malignant transformation (41) . It would be quite interesting to know whether YKL-40 plays an active role in these evasion responses.
Nevertheless, the combined anti-angiogenic approaches that include anti-angiogenic monoclonal antibodies and membrane receptor kinase inhibitors together with other chemotherapies pave the way towards a more efficacious therapy for cancer patients. 29 from U87 cells in the presence or absence of 10 g/ml mIgG or mAY was transferred to HMVECs for 24 hr as described in Figure 3A . Subsequently, all of the cell lysates were tested for Flk-1/KDR expression by immunoblotting. Flk-1/KDR data were normalized with actin levels and then compared with the basal serum-free level arranged as one unit. HMVECs were pretreated with serum-free medium overnight and then treated for 10 min with U87 cell conditioned medium that was exposed to mAY or mIgG (10 g/ml) for 24
hr. Half of the cell lysates were immunoprecipitated with an antibody against phosphorylated tyrosine protein (pY20) followed by immunoblotting using an antibody against Flk-1/KDR. The remaining lysates were used directly for immunoblotting against total Flk-1/KDR. IgG of the anti-pY20 antibody was also tested as loading controls.
pFlk-1/KDR was normalized with total Flk-1/KDR. n=3, mean SE. C. mAY blocks
YKL-40-induced MAPK Erk 1 and Erk 2 activation.
The same conditions of HMVECs as described in B were collected and immunoblotted with antibodies against pErk 1, Erk 2, and total Erk followed by quantification. pErk 1 and pErk 2 levels were normalized with total Erk 1 and Erk 2. SF indicates serum-free basal DMEM and Con represents DMEM serum-free conditioned medium alone. n=2, mean SE. 
